Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence (Q35641628)

9 August 2017

1 reference

title

Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence (English)

1 reference

9 August 2017

1 reference

1 reference

1 reference

Julian Segura

2

0 references

Luis Miguel Ruilope

object named as

Luis M Ruilope

series ordinal

1

0 references

publication date

1 December 2003

1 reference

9 August 2017

published in

Clinical Therapeutics

1 reference

9 August 2017

volume

25

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

3044-3064

1 reference

Renal disease and hypertension in non-insulin-dependent diabetes mellitus.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Hypertension and diabetes: new therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Optimizing treatment of hypertension in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Global and societal implications of the diabetes epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

The progressive cost of complications in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Proteinuria: its clinical importance and role in progressive renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Pathogenesis, prevention, and treatment of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Nephropathy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Angiotensin receptor antagonists: focus on losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Angiotensin receptors and their antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Renoprotective therapy: titration against urinary protein excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Comparison of losartan and amlodipine in renally impaired hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Optimal dose of losartan for renoprotection in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Angiotensin-II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Effects of losartan on renal function in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

A randomized, double-blind, parallel study on the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Losartan and diabetic nephropathy: commentaries on the RENAAL study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Prevention of end-stage renal disease due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Serum creatinine levels in older adults: relationship with health status and medications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Restrictions on use of creatinine clearance for measurement of renal functional reserve

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

Role of angiotensin II in diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2990091-9

7 January 2021

10.1016/S0149-2918(03)90091-9

Identifiers

DOI

1 reference

9 August 2017

1 reference